NIDA Boosts Research and Development of Medical Devices for Substance use Disorder via the NIH Blueprint MedTech Initiative.
Subst Use Misuse
; 58(5): 735-738, 2023.
Article
in En
| MEDLINE
| ID: mdl-36866964
ABSTRACT
Background:
Deaths from drug overdose have reached a crisis level, with more than 100,000 reported from April 2020 to April 2021. Novel approaches to address it are urgently needed.Objectives:
National Institute on Drug Abuse (NIDA) is leading novel comprehensive efforts to develop safe and effective products that address the needs of the citizens affected by SUD. NIDA aims to support research and development of medical devices intended to monitor, diagnose, or treat substance use disorders.Results:
NIDA participates in Blueprint MedTech program is part of the large NIH Blueprint for Neurological Research Initiative. It supports the research and development of new medical devices through product optimization, pre-clinical testing, and human subject studies, including clinical trials. The program is structured in two main components - Blueprint MedTech Incubator and Blueprint MedTech Translator. It offers free to the researcher services that are typically unavailable in academic environment - business expertise facilities and staffing to successfully develop minimum viable devices, pre-clinical bench testing, clinical studies, planning and executing in manufacturing, as well as regulatory expertise.Conclusions:
Through Blueprint MedTech, NIDA provides innovators with expanded resources to ensure the success of the research.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Substance-Related Disorders
/
Drug Overdose
Type of study:
Diagnostic_studies
Limits:
Humans
Country/Region as subject:
America do norte
Language:
En
Journal:
Subst Use Misuse
Journal subject:
TRANSTORNOS RELACIONADOS COM SUBSTANCIAS
Year:
2023
Document type:
Article